Nimotuzumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	31	18	25	105	—	—	Jan 1, 2002
Malignant Nasopharyngeal Neoplasm	Phase4	Phase 4	6	6	4	13	—	—	2009-10
Malignant Pancreatic Neoplasm	Phase3	Phase 3	6	2	3	11	—	—	2007-09
Malignant Esophageal Neoplasm	Phase3	Phase 3	5	4	5	17

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Overexpression1
Nimotuzumab	Esophageal Squamous Cell Carcinoma

Clinical trials

Trials with this intervention (109)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 109 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07821242	Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma(NCRHNC)	not yet recruiting	Phase 2	46	Ke HuOTHER	1	Sep 15, 2026	clinicaltrials
NCT07736612	A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer	not yet recruiting